Evidence Based Probiotics Supplements Australia
Evidence Based Probiotics is an Australian supplier carrying a small, deliberately selected range of probiotic products – each built around a single, named strain with its own independent research history. The range currently includes two products: Yomogi, a yeast-based probiotic, and Mutaflor, a bacterial probiotic with an unusually long clinical record.
The distinguishing feature of this range is strain specificity. Both products are defined by exact strain identity – S. boulardii HANSEN CBS 5926 and E. coli Nissle 1917 – rather than species-level generics. This matters because the research literature attaches to the specific isolate, not the broader species, meaning the evidence base applies directly to what is in the product.
| Product Range | Primary Application |
|---|---|
| Yomogi S. boulardii (HANSEN CBS 5926) | Short-term gut support, periods of antibiotic use, acute gut disruption |
| Mutaflor (E. coli Nissle 1917) | Gut microbiome restoration, longer-term gut resilience |
The practical question for most people is not whether to use a specific probiotic strain – it is which one suits the situation. These two products serve different roles and are not interchangeable.
Why Evidence Based Probiotics’ approach is different
Most probiotic products identify their contents by species name only – for example, “Saccharomyces boulardii” or “Lactobacillus acidophilus” – without naming the specific isolate. Different isolates within the same species can behave differently: they have different surface structures, interact with the gut lining differently, and have been studied for different applications. CBS 5926 is the pharmaceutical reference strain for S. boulardii – the isolate used in the majority of clinical trials on this species – which means that when you read published research on S. boulardii, it is almost always CBS 5926 that was tested.
E. coli Nissle 1917 is a non-pathogenic commensal strain – meaning it does not cause illness and belongs to the category of E. coli that naturally inhabits a healthy gut, not the enterotoxigenic strains associated with food contamination. The “1917” in the name is the actual year of isolation; this specific strain has been in continuous clinical study since then, making it one of the most thoroughly documented probiotic organisms in existence. Both strains have strain-specific production standards that govern how they are grown, stabilised, and packaged – standards that do not apply to generic species-level products.
The Evidence Based Probiotics range at Fairfield Nutrition
| Product | Best For | Key Ingredient(s) |
|---|---|---|
| Yomogi S. boulardii Probiotic | Gut disruption during or after antibiotic use, acute gut imbalance, travel-related gut stress | Saccharomyces cerevisiae (boulardii) HANSEN CBS 5926 |
| Mutaflor Probiotic | Gut microbiome restoration, longer-term gut resilience, post-disruption gut environment support | Escherichia coli Nissle 1917 (non-pathogenic commensal strain) |
The choice between these two products comes down to the nature of the probiotic and the intended timeframe. Yomogi is yeast-based, which means it is unaffected by antibiotics and suits shorter, targeted courses – it is often used during or immediately after antibiotic therapy. Mutaflor is bacterial and better suited to longer-term support aimed at establishing or restoring a stable gut environment. The two are sometimes used sequentially, but neither functions as a general-purpose probiotic blend – each has a specific evidence base that shapes when and how it is used.
Why shop Evidence Based Probiotics at Fairfield Nutrition
We don’t stock everything – we stock what we’d use. Evidence Based Probiotics products are stocked at Fairfield because both strains represent the benchmark references in their respective research fields – CBS 5926 and Nissle 1917 are the specific isolates the published clinical literature is built around, not proxies or comparators.
Mutaflor is not widely available in Australia. It requires cold-chain handling throughout the supply chain and has specific import and storage requirements. Stocking it is a deliberate choice driven by the depth of the Nissle 1917 evidence base – this is a product that is genuinely difficult to source reliably in this market, and that difficulty does not change the clinical case for it.
Yomogi is sourced to the HANSEN CBS 5926 pharmaceutical specification – the same strain standard used in the majority of published S. boulardii trials. Not all S. boulardii products in the Australian market specify their strain to this level. When the product matches the research strain, the published data applies directly.
All Evidence Based Probiotics products stocked at Fairfield Nutrition are shown below.
